IMCI Pharmaceuticals
IMCI is Making Medical Cannabis: Safer, Effective, and Patient-Focused
Company Overview
Snapshot
Founded in December 2018 by Alon Hershkovitz and Avi Yakobovich, IMCI Pharmaceuticals operates with 1–10 employees. The company is currently in a Pre-Funding stage, focusing on advancing medical cannabis solutions. In September 2024, IMCI Pharmaceuticals was featured for its innovative approach to safer medical cannabis.
Business overview
IMCI Pharmaceuticals is a pharma-grade medical cannabis company dedicated to enhancing patient care through scientific advancements, safety protocols, and precision. The company's core technology is the proprietary NanoVATE™ drug-delivery platform, designed to improve cannabinoid bioavailability for fast, accurate, and long-lasting relief. IMCI Pharmaceuticals serves global markets with its iCann product line, including iCann Fast, iCann Oral, and iCann LA, targeting patients in Europe, Israel, and the U.S. with standardized, effective, and stigma-free cannabis treatments. The company operates within the Health Tech & Life Sciences sector, specifically focusing on Pharma & Medical Biotechnology, Medical Cannabis, and Drugs Discovery & Development.
Strategic signal
In September 2024, IMCI Pharmaceuticals gained recognition for its innovative approach to medical cannabis, highlighted in an article titled 'No Smoking! Startup's To Safer Medical Cannabis'. This signals the company's commitment to addressing patient needs through advanced drug delivery and product development, positioning it as a key player in the evolving medical cannabis landscape and indicating potential for future growth and market penetration.
Company Intelligence Q&A
- What is IMCI Pharmaceuticals' primary focus?
- IMCI Pharmaceuticals focuses on redefining patient care through science, safety, and precision in the medical cannabis sector, utilizing its proprietary NanoVATE™ drug-delivery platform to enhance cannabinoid bioavailability.
- When was IMCI Pharmaceuticals founded and by whom?
- IMCI Pharmaceuticals was founded in December 2018 by Alon Hershkovitz and Avi Yakobovich.
- What is the NanoVATE™ drug-delivery platform?
- The NanoVATE™ drug-delivery platform is IMCI Pharmaceuticals' proprietary technology designed to enhance cannabinoid bioavailability, enabling fast, accurate, and long-lasting relief through its iCann product line.
- Which markets does IMCI Pharmaceuticals target?
- IMCI Pharmaceuticals is expanding across Europe, Israel, and the U.S., aiming to bring standardized, effective, and stigma-free cannabis treatments to these global markets.
- What was a recent notable mention for IMCI Pharmaceuticals?
- In September 2024, IMCI Pharmaceuticals was featured in an article by nocamels.com, highlighting its innovative approach to safer medical cannabis.